EP0987998B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Tissue decellularization
Assignee: Artivion Inc
•
Filing: 1998-04-10
•
Granted: 2004-10-13
•
Expires: 2018-04-10
Abstract
Abstract The present invention relates, in general, to tissue decellularization and, in particular to a method of treating tissues, for example, heart valves, tendons and ligaments, so as to render them acellular and thereby limit mineralization and/or immunoreactivity upon implementation in vivo.
Inventors
- 👤 Steven Goldstein
- 👤 Kirby S. Black
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 00:05
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/3683; A61L27/3695; A61L27/3604; A61L27/3687; A61F; A61F2/00; A61F2/02; A61F2/24; A61F2/2412; A61F2/2415; A61L2400/00; A61L2400/02; A61L2430/00; A61L2430/40; Y; Y10; Y10S; Y10S623/00; Y10S623/915; Y10S623/916; Y10S623/918
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
144 words
A method of manufacturing a medicament for treating
a mammal to replace a defective tissue in the mammal, wherein
the defective tissue is selected from the group consisting of
a heart valve, tendon, ligament, artery, vein, diaphragm,
pericardium, fascia, dura mater and tympanic membrane,
wherein the medicament comprises a bioprosthetic tissue that
is decellularized and unfixed, and wherein the method
comprises the steps of: (i) washing a starting tissue with an antibiotic
so that said starting tissue is disinfected, wherein
the starting tissue is selected from the group consisting of
a heart valve, tendon, ligament, artery, vein, diaphragm,
pericardium, fascia, dura mater and tympanic membrane; (ii) subsequent to step (i), contacting said disinfected
tissue with a hypotonic solution so that lysis of cells of
said disinfected tissue is effected; and (iii) incubating the hypotonic solution-treated tissue
resulting from step (ii) with a nuclease solution.
Claim 2
Dependent Claim
27 words
The method according to claim 1, wherein the method
further comprises: (iv) after step (iii), contacting the tissue resulting
from step (iii) with a physiologically isotonic solution.
Claim 3
Dependent Claim
13 words
The method according to claim 1 wherein said starting
tissue is human tissue.
Claim 4
Dependent Claim
15 words
The method according to claim 3 wherein said starting
tissue is human heart valve tissue.
Claim 5
Dependent Claim
19 words
The method according to claim 1 wherein said tissue
resulting from step (iii) is at least 70 % decellularized.
Claim 6
Dependent Claim
14 words
The method according to claim 1 wherein the nuclease
solution contains DNAase or RNAase.
Claim 7
Dependent Claim
14 words
The method according to claim 1 wherein the nuclease
solution contains DNAase and RNAase.
Claim 8
Dependent Claim
13 words
The method according to claim 1 wherein said starting
tissue is non-human tissue.
Claim 9
Dependent Claim
23 words
The method according to claim 1 wherein said step (ii)
is carried out at a temperature in the range of 30°C to 40°C.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.